Europe’s health policies ‘must change’ with stakeholders leaving their ‘comfort zones’
24 Oct 2014
“Patients are waiting for therapeutic improvement and asking us – while we have good technologies – are we really bringing them the best new drugs? And if we look hard in the mirror the fact is that we are not using technology optimally”, said Dr. Denis Lacombe, EORTC Director. “There needs to be more collaboration, new models…and that means we have to think outside the box.”
Read the entire interview here
Related News
In Memoriam: Neil Aaronson, founding member of the EORTC Quality of Life Group
7 Sep 2026
New EORTC perspective calls for patient preferences to become a standard part of cancer trials for older adults
4 Sep 2026
New EORTC questionnaire sets a global standard for measuring quality of life in cancer survivors
25 Aug 2026
Final results of ARCAGEN – An EORTC-SPECTA and EURACAN initiative for molecular profiling and access to treatment for rare cancers
23 Jul 2026
EORTC calls for a balanced and feasible European Health Data Space (EHDS)
8 Jul 2026
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
